(Q82326317)
Statements
Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours (English)
N Isambert
M Campone
E Bourbouloux
M Drouin
A Major
W Yin
R Capizzi
C Grieshaber
22 December 2009